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Objectives The objectives of this study were to evaluate outcomes of pulmonary valve replacement (PVR) in patients with
chronic pulmonary regurgitation (PR) and to better define the optimal timing of PVR.
Background Although PVR is effective in reducing right ventricular (RV) volume overload in patients with chronic PR, the opti-
mal timing of PVR is not well defined.
Methods A total of 170 patients who underwent PVR between January 1998 and March 2011 for chronic PR were retro-
spectively analyzed. To define the optimal timing of PVR, pre-operative and post-operative cardiac magnetic res-
onance imaging (MRI) data (n  67) were analyzed.
Results The median age at the time of PVR was 16.7 years. Follow-up completeness was 95%, and the median
follow-up duration was 5.9 years. Overall and event-free survival at 10 years was 98% and 70%, respectively.
Post-operative MRI showed significant reduction in RV volumes and significant improvement in biventricular
function. Receiver-operating characteristic curve analysis revealed a cutoff value of 168 ml/m2 for non-
normalization of RV end-diastolic volume index (EDVI) and 80 ml/m2 for RV end-systolic volume index (ESVI).
Cutoff values for optimal outcome (normalized RV volumes and function) were 163 ml/m2 for RV EDVI and
80 ml/m2 for RV ESVI. Higher pre-operative RV ESVI was identified as a sole independent risk factor for subopti-
mal outcome.
Conclusions Midterm outcomes of PVR in patients with chronic PR were acceptable. PVR should be considered before RV
EDVI exceeds 163 ml/m2 or RV ESVI exceeds 80 ml/m2, with more attention to RV ESVI. (J Am Coll Cardiol
2012;60:1005–14) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.077a
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pRelief of right ventricular (RV) outflow tract obstruction in
tetralogy of Fallot or similar physiology often results in
pulmonary regurgitation (PR). The resultant chronic vol-
ume overload can lead to RV dilation, biventricular dysfunc-
tion, heart failure symptoms, arrhythmias, and sudden death
(1–5). Pulmonary valve replacement (PVR) can lead to
mprovement in functional class and a substantial decrease
r normalization of RV volumes (6,7). Other potential
enefits of PVR are improvement in exercise capacity (8)
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H2012, accepted March 29, 2012.nd decrease in QRS duration (9). However, benefits of
VR have to be weighed against the risks of this procedure.
See page 1015
Although operative mortality of PVR is low (6), post-
perative morbidities are not negligible (10) and patients are
xposed to the risk of repeat PVR (11–13). PVR is indicated
hen patients become symptomatic or at risk for life-
hreatening arrhythmias (14). For asymptomatic patients,
here have been debates regarding the optimal timing of
VR (15–19). Magnetic resonance imaging (MRI) is a gold
tandard for evaluating RV volumes and function (20), and
hese MRI parameters can be used to decide the indications
or PVR. Many studies dealing with changes in MRI
arameters after PVR have been reported (7–9,21–26).
owever, most of them have a limitation of small patient
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ies suggesting the optimal timing
of PVR (7–9). The objectives of
this study were to evaluate out-
comes of PVR performed in pa-
tients with chronic PR and to
better define the optimal timing of
PVR by analyzing MRI parameters.
Methods
Patients. Between January 1998
and March 2011, 170 patients
underwent surgical PVR for
chronic PR after repair of tetral-
ogy of Fallot or similar physiol-
ogy. Patients with significant val-
vular and/or subvalvular pulmonary
stenosis, RV to pulmonary artery
conduits, and other significant
confounding congenital heart
iseases were excluded. Indications for PVR were symptoms
nd signs attributable to RV volume overload, presence of
ignificant associated lesions such as branch pulmonary
rtery stenosis and tricuspid regurgitation, and sustained
achyarrhythmias. For asymptomatic patients, we prescribed
VR when RV end-diastolic volume index (EDVI) assessed
y MRI approached 170 ml/m2. The institutional review
oard of Sejong General Hospital approved this retrospec-
ive study. Data were obtained by review of medical records
nd direct telephone contact. Table 1 summarizes the
emographic and preoperative characteristics of the study
atients.
urgical procedures. PVR was performed through median
ternotomy on cardiopulmonary bypass with mild hypother-
ia. Aortic cross-clamping was dependent on the surgeon’s
reference or on concomitant procedures. Choice of pros-
hetic pulmonary valves was at the discretion of the surgeon.
hen deemed necessary, RV reduction (aneurysm resec-
ion/plication/exclusion or RV remodeling) was performed
ccording to the surgeon’s preference. Table 2 summarizes
he surgical data.
ardiac MRI. Since 2002, we have performed cardiac
RI as a part of routine pre-operative evaluation for PVR,
nd 118 patients (69%) have undergone the procedure.
mong these, 67 patients (57%) underwent post-operative
RI at a median of 9.7 months (1.1 months to 7.1 years)
fter PVR. Six patients underwent only post-operative MRI
ithout pre-operative MRI. Therefore, post-operative MRI
ata were available in 73 patients.
Studies were performed with a 1.5-T Gyroscan Intera
V system (Philips Medical Systems, Best, the Nether-
ands). A multiphase acquisition was obtained using a
teady-state free precession pulse sequence in 2- and
-chamber planes. From these images, 10 to 12 contiguous
Abbreviations
and Acronyms
EDVI  end-diastolic
volume index
EF  ejection fraction
ESVI  end-systolic volume
index
LV  left
ventricle/ventricular
MRI  magnetic resonance
imaging
PR  pulmonary
regurgitation
PVR  pulmonary valve
replacement
RV  right
ventricle/ventricular
VT  ventricular
tachycardiahort-axis slabs perpendicular to the long axis of the left Wentricle (LV) were obtained (slice thickness 6 to 8 mm;
nterslice gap 0 to 2 mm). Biventricular volumetric analysis
as performed using Extended MR Workspace software
Philips Medical Systems). For the evaluation of PR,
hrough-plane velocity imaging perpendicular to the main
ulmonary artery was performed using a breath-holding,
lectrocardiogram-triggered, cine phase contrast pulse se-
uence. Forward and regurgitant pulmonary volume flow was
easured from the velocity-encoded images by manually trac-
ng the main pulmonary artery contour. Flow volumes were
alculated by multiplying contour area by average flow velocity
ithin the contour. Flow volumes were summed to give total
orward flow and total regurgitant flow per cardiac cycle.
Demographic andPre-Operative Characteristics of the PatientsTable 1 Demographic andPre-Operative Characteristics of the Patients
Male/female 103/67
Fundamental diagnosis
TOF 139 (82)
PA with VSD 15 (9)
DORV (TOF type) 14 (8)
APVS 2 (1)
Age at repair, yrs 2.0 (0.2–44.1)
Type of RVOT reconstruction
Transannular patch 124 (73)
Pulmonary valvotomy 26 (15)
Monocusp valve 20 (12)
No. of prior operations before PVR 1.4 0.6
Age at PVR, yrs 16.7 (4.6–60.2)
Interval between repair and PVR, yrs 13.8 (4.0–27.5)
NYHA functional class*
I 65 (38)
II 91 (54)
III 12 (7)
IV 1 (1)
TR grade*
None 9 (5)
Trivial 60 (35)
Mild 83 (49)
Moderate 13 (8)
Severe 4 (2)
QRS duration (n  79), ms† 147 (85–203)
Arrhythmia
AFL 4 (2)
AF 3 (2)
VT 3 (2)
AV block 3 (2)
SA node dysfunction 3 (2)
Others 4 (2)
Cardiopulmonary exercise test (n  42)
Peak VO2, ml/kg/min 30 (11–40)
% Predicted peak VO2, % 75 (21–115)
Values are n, n (%), median (range), or mean SD. *Data not available for 1 patient. †QRS180
ms in 7 patients.
AF  atrial fibrillation; AFL  atrial flutter; APVS  absent pulmonary valve syndrome; AV 
atrioventricular; DORV  double outlet right ventricle; NYHA  New York Heart Association; PA 
pulmonary atresia; PVR  pulmonary valve replacement; RVOT  right ventricular outflow tract;
SA sinoatrial; TOF tetralogy of Fallot; TR tricuspid regurgitation; VO2 oxygen consumption;
SD  ventricular septal defect; VT  ventricular tachycardia.hen significant artifacts by prosthetic valves made direct
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September 11, 2012:1005–14 Optimal Timing of Pulmonary Valve Replacementmeasurement of PR difficult in post-operative patients, we
used branch pulmonary artery maps to measure PR.
Stroke volume was calculated by deducting end-systolic
volume from end-diastolic volume, and ejection fraction
(EF) was calculated as percent stroke volume divided by
end-diastolic volume. Effective RV stroke volume was
calculated by deducting backward flow volume from forward
flow volume to reflect the net forward blood flow into the
pulmonary arteries. Corrected RV EF was calculated as
percent effective RV stroke volume divided by RV end-
diastolic volume (27). PR fraction was calculated as percent
ackward flow divided by forward flow.
ollow-up. Follow-up was considered complete if the pa-
ient’s status was determined after July 2010. The median
uration of follow-up was 5.9 years (0.3 to 13.5 years), and
7.5% of hospital survivors had complete follow-up.
ollow-up completeness measured by calculating the Clark
ndex (28) was 94.8%. The most recent electrocardiographic
nd echocardiographic data were used for analyses. If
ecessary, patients underwent Holter examinations to detect
rrhythmias and cardiopulmonary exercise testing to deter-
ine exercise tolerance.
efinitions of outcomes. Prosthetic pulmonary valve fail-
re was defined as the need for redo PVR or interventional
atheter procedure. Prosthetic pulmonary valve dysfunction
as defined as a peak pressure gradient 40 mm Hg or at
east moderate PR on the latest echocardiography. Arrhyth-
ia was defined as sustained atrial fibrillation, atrial flutter,
r ventricular tachycardia (VT). Event was defined as redo
VR, interventional catheter procedure for prosthetic pul-
Surgical DataTable 2 Surgical Data
Type of prosthetic pulmonary valve
Stented bovine pericardial valve 76 (45)
Stented porcine valve 57 (34)
PTFE bicuspid valve 30 (18)
Stentless porcine valve 7 (4)
Size of prosthetic pulmonary valve, mm 25 (19–30)
Concomitant procedures
PA angioplasty 91 (54)
RV reduction 84 (49)
TV repair 27 (16)
VSD closure 16 (9)
ASD closure 6 (4)
RA isthmus cryoablation 5 (3)
Right-sided maze procedure 3 (2)
RVOT cryoablation 2 (1)
Biatrial maze procedure 1 (1)
TV replacement 1 (1)
Others 11 (7)
CPB time, min 149 77
ACC time (n  70), min 77 35
Values are n (%), median (range), or mean  SD.
ACC  aortic cross-clamp; ASD  atrial septal defect; CPB  cardiopulmonary bypass; PA 
pulmonary artery; PTFE  polytetrafluoroethylene; RA  right atrial; RV  right ventricle; TV 
tricuspid valve; other abbreviations as in Table 1.onary valve, arrhythmia, or all-cause death. Optimalutcome in terms of MRI parameters was defined as normal
V EDVI (108 ml/m2), end-systolic volume index
ESVI) (47 ml/m2), and function (EF 49%) (29).
tatistical analysis. Data were expressed as frequency (%),
edian (range), or mean  SD as appropriate. Assessment of
he association between 2 continuous variables was performed
sing linear regression analysis. Comparisons between paired
roups were performed using paired t tests or Wilcoxon signed
rank tests as appropriate. Comparisons between independent
groups were performed using Mann-Whitney tests. Discrete
variables were analyzed using chi-square tests. Survival and
time-to-event analyses were performed using the Kaplan-
Meier method. Cutoff values of pre-operative RV volumes for
normalization of RV volumes and optimal outcome were
identified using receiver-operating characteristic curve analysis.
We considered situations in which surgery was performed “too
early” or “too late” equally adverse. Therefore, we selected the
point at which sensitivity and specificity were equal (9).
Independent predictors for suboptimal outcome were identi-
fied using multivariable binary logistic regression analysis.
Variables that achieved p  0.05 in the univariable analysis
entered the multivariable analysis. SPSS version 18.0 (SPSS
Inc., Chicago, Illinois) was used for statistical analysis, and p
0.05 was considered statistically significant.
Results
Pre-operative MRI parameters. Table 3 summarizes the
pre-operative MRI parameters, and Figure 1 shows the
correlations between MRI parameters. RV EDVI was
strongly associated with RV ESVI. Higher PR fraction was
associated with increasing RV volumes. However, PR frac-
tion was not associated with RV EF (r  0.01; p  0.96).
Lower RV EF was associated with increasing RV volumes
and lower LV EF. LV EF was not associated with RV
volumes (EDVI [r  0.09; p  0.33] and ESVI [r 
0.17; p  0.07]). Longer QRS duration was associated
with increasing RV volumes (EDVI [r  0.46; p  0.001]
and ESVI [r  0.57; p  0.001]; n  63).
Pre-Operative MRI Parameters (n  118)Table 3 Pre-Operative MRI Parameters (n  118)
RV EDVI, ml/m2 164 39
RV ESVI, ml/m2 85 34
RV SVI, ml/m2 79 17
RV EF, % 49 9
Corrected RV EF, %* 26 8
PR fraction, %* 47 10
LV EDVI, ml/m2 78 15
LV ESVI, ml/m2 32 11
LV SVI, m/m2 46 10
LV EF, % 60 7
RV/LV EDV 2.1 0.5
Values are mean  SD. *Data not available for 1 patient owing to artifacts.
EDV  end-diastolic volume; EDVI  end-diastolic volume index; EF  ejection fraction; ESVI end-systolic volume index; LV  left ventricular; PR  pulmonary regurgitation; RV  right
ventricular; SVI  stroke volume index.
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deaths (1.2%) due to ischemic brain injury and RV dysfunc-
tion. There was 1 late death by an accident. Overall survival
at 10 years was 97.5  1.6% (Fig. 2A). Twelve patients
underwent redo PVR, and 2 patients underwent interven-
tional balloon valvuloplasty. Freedom from redo PVR at 10
years was 74.7  10.0%, and freedom from prosthetic valve
failure and dysfunction at 10 years was 50.3  10.1% (Figs. 2B
Figure 1 Associations Between Pre-Operative MRI Parameters
n  117 (1 outlier excluded). (A) Association between right ventricular (RV) end-di
between pulmonary regurgitation (PR) fraction and RV EDVI. (C) Association betwe
RV EDVI. (E) Association between RV EF and RV ESVI. (F) Association between RVand 2C). Two patients developed atrial fibrillation, and 1patient developed atrial flutter. No patient developed VT.
QRS duration decreased significantly (145  29 ms vs.
139  26 ms; p  0.002, n  78), and 3 patients had QRS
duration of 180 ms. Freedom from arrhythmia at 10 years
was 99.2 0.7%. Overall event-free survival at 10 years was
69  10.5% (Fig. 2D).
New York Heart Association functional class improved
from 1.7 0.6 to 1.1 0.3 (p 0.001). The proportion of
volume index (EDVI) and RV end-systolic volume index (ESVI). (B) Association
fraction and RV ESVI. (D) Association between RV ejection fraction (EF) and
d left ventricular (LV) EF. MRI  magnetic resonance imaging.astolic
en PR
EF anpatients with tricuspid regurgitation grade of at least mod-
3c
t
t
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September 11, 2012:1005–14 Optimal Timing of Pulmonary Valve Replacementerate decreased significantly (10% vs. 0%; p  0.001).
Cardiopulmonary exercise testing data (n  15) showed no
change in peak oxygen consumption (30  6 ml/kg/min vs.
0  5 ml/kg/min; p  0.43).
Figure 2 Kaplan-Meier Curves
(A) Overall survival. (B) Freedom from redo pulmonary valve replacement (PVR). (C
Numbers above the x-axis represent patients remaining at risk.
Changes in MRI Parameters (n  67)Table 4 Changes in MRI Parameters (n  6
Parameter Pre-PVR
RV EDVI, ml/m2 166 41
RV ESVI, ml/m2 88 38
RV SVI, ml/m2 77 17
Effective RV SVI, ml/m2* 40 9
RV EF, % 48 10
PR fraction, % 46 10
LV EDVI, ml/m2 78 17
LV ESVI, ml/m2 32 12
LV SVI, ml/m2 46 8
LV EF, % 60 7
RV/LV EDV 2.2 0.5Values are mean  SD. *Data not available for 9 patients.
Abbreviations as in Table 3.Changes in MRI parameters. Table 4 summarizes the
hanges in MRI parameters, and Figure 3 shows the correla-
ions between MRI parameters. There were significant reduc-
ion in RV volumes, improvement in biventricular function,
dom from prosthetic valve failure and dysfunction. (D) Event-free survival.
ost-PVR % Change p Value
03 25 37 11 0.001
49 22 42 16 0.001
53 12 29 16 0.001
47 9 23 36 0.001
53 8 15 24 0.001
7 6 84 15 0.001
83 19 9 18 0.003
32 10 4 29 0.844
51 12 13 21 0.001
62 6 4 13 0.046
.2 0.3 41 13 0.001) Free7)
P
1
1
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Optimal Timing of Pulmonary Valve Replacement September 11, 2012:1005–14and increase in LV EDVI. Pre-operative RV volumes were
associated with post-operative RV volumes and absolute de-
crease in RV volumes. Post-operative RV EF was associated
with pre-operative and post-operative RV ESVI.
Cutoff values for normalization of RV volumes and
optimal outcome (n  67). RV EDVI was normalized in
65% of the patients, and RV ESVI was normalized in 52%.
Figure 3 Associations Between Pre- and Post-Operative MRI P
n  66 (1 outlier excluded). (A) Association between pre- and post-operative RV E
between pre-operative RV EDVI and absolute decrease in RV EDVI. (D) Association
between pre-operative RV ESVI and post-operative RV EF. (F) Association betweenOptimal outcome in terms of MRI parameters was achieved
in 51% of the patients. No patient with optimal MRI
outcome had a poor clinical outcome such as death or
arrhythmia. A cutoff value of pre-operative RV EDVI for
normalization of RV EDVI was 168 ml/m2 (sensitivity
74%; specificity 74%), and a cutoff value of pre-operative
RV ESVI for normalization of RV ESVI was 80 ml/m2
eters
) Association between pre- and post-operative RV ESVI. (C) Association
een pre-operative RV ESVI and absolute decrease in RV ESVI. (E) Association
perative RV ESVI and RV EF. Abbreviations as in Figure 1.aram
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September 11, 2012:1005–14 Optimal Timing of Pulmonary Valve Replacement(sensitivity 68%; specificity 68%) (Figs. 4A and 4B). Cutoff
values of pre-operative RV EDVI and ESVI for optimal
outcome were 163 ml/m2 (sensitivity 69%; specificity 70%)
nd 80 ml/m2 (sensitivity 69%; specificity 70%), respectively
(Figs. 4C and 4D).
Predictors for suboptimal outcome. Table 5 summarizes
the comparison between patients with optimal versus sub-
optimal outcome. Patients with optimal outcome had
significantly lower pre-operative RV volumes and higher
pre-operative RV function. In univariable analysis, higher
pre-operative RV volume indexes, lower pre-operative
RV EF, and lower pre-operative corrected RV EF were
identified as risk factors for suboptimal outcome. In
multivariable analysis, higher preoperative RV ESVI was
identified as a sole independent risk factor for suboptimal
outcome (Table 6).
Figure 4 Receiver-Operating Characteristic Curves
n  67. Receiver-operating characteristic (ROC) curves were calculated to determi
(B) pre-operative RV ESVI for normalization of RV ESVI, (C) pre-operative RV EDVI
Ranges in parentheses represent 95% confidence intervals for the area under theiscussion
re-operative MRI parameters. Chronic PR after relief of
V outflow tract obstruction can lead to RV dilation,
iventricular dysfunction, heart failure symptoms, arrhyth-
ias, and sudden death (1–5). Previous studies have dem-
nstrated a close relationship between the degree of PR and
V volumes (4,30), and our study has reconfirmed this
nding. The finding that PR fraction was more closely
ssociated with RV EDVI compared with RV ESVI in
revious studies and our studies might reflect the adaptive
V response to volume overload and the time sequence of
V dilation (5,31). Also consistent with previous studies
4,30), lower RV EF was more closely associated with
igher RV ESVI compared with RV EDVI, and this
nding might also reflect the pathophysiological sequence
utoff value of (A) pre-operative RV EDVI for normalization of RV EDVI,
imal outcome, and (D) pre-operative RV ESVI for optimal outcome.
(AUC). Abbreviations as in Figure 1.ne a c
for opt
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ated with lower RV EF, suggesting adverse RV to LV
interaction (4,20). Longer QRS duration was associated
with larger RV volumes, as demonstrated in previous studies
(4,32,33), and this association supports the notion that QRS
prolongation is a marker of RV dilation. To summarize,
analysis of the preoperative MRI parameters showed patho-
physiological consequences of chronic PR.
Clinical outcomes. Nowadays, PVR can be performed
with low operative mortality as evidenced by our result
(1.2%) and others (1% to 4%) (6). Midterm survival after
PVR is also satisfactory as evidenced by our result (98% at
10 years) and others (86% to 98% at 10 years) (13,14,34,35).
owever, there are no published data showing a clear
Comparison Between PatientsWith Optimal Versus Suboptimal OutcomeTable 5 Comparison Be ween PatientsWith Optimal Versus Suboptimal Outcome
Variable
Optimal
(n  33)
Suboptimal
(n  32) p Value
Age, yrs 18.5 6.0 18.9 8.4 0.641
Age at repair, yrs 3.2 3.1 4.9 8.5 0.267
RV EDVI, ml/m2 148 35 184 39 0.001
RV ESVI, ml/m2 73 25 104 43 0.001
RV EF, % 51 8 45 10 0.014
Corrected RV EF, % 28 8 23 7 0.004
PR fraction, % 46 10 47 10 0.466
LV EDVI, ml/m2 74 14 82 19 0.012
LV ESVI, ml/m2 31 10 34 13 0.415
LV EF, % 61 6 59 9 0.864
FU RV EDVI, ml/m2 85 11 120 22 0.001
FU RV ESVI, ml/m2 37 8 63 23 0.001
FU RV EF, % 57 7 49 7 0.001
FU PR fraction, % 6 4 8 8 1.000
FU LV EDVI, ml/m2 79 14 88 22 0.023
FU LV ESVI, ml/m2 30 8 35 11 0.046
FU LV EF, % 62 6 62 7 0.646
QRS, ms 137 26 (n 14) 152 28 (n 20) 0.192
FU QRS, ms 136 26 (n 32) 152 21 (n 31) 0.013
Values are mean SD. Optimal outcome was defined as normalized RV EDVI (108 ml/m2), ESVI
(47 ml/m2), and function (EF 49%).
FU  follow-up; other abbreviations as in Table 3.
Independent Predictors for Suboptimal OutcomeTable 6 Independent Predictors for Suboptim
Predictor
Univariable Analy
OR (95% CI)
Age at PVR, yrs 1.01 (0.94–1.08)
Age at repair, yrs 1.05 (0.91–1.14)
RV EDVI, ml/m2* 1.03 (1.01–1.06)
RV ESVI, ml/m2 1.05 (1.02–1.08)
RV EF, % 0.92 (0.86–0.98)
Corrected RV EF, % 0.90 (0.83–0.98)
PR fraction, % 1.02 (0.97–1.07)
LV EDVI, ml/m2 1.04 (1.00–1.07)
LV ESVI, ml/m2 1.02 (0.98–1.07)
LV EF, % 0.98 (0.91–1.05)*RV EDVI was not entered into the multivariable analysis because of the stro
CI  confidence intervals; OR  odds ratio; other abbreviations as in Tableong-term survival benefit of PVR. Gengsakul et al. (36), in
matched comparison study, reported that there was no
ifference regarding the composite outcome of death and
T between PVR and non-PVR patients. Recently Harrild
t al. (26) also reported similar results.
In our study, most of the events during follow-up were
edo PVR. Although freedom from redo PVR seemed
cceptable (75% at 10 years), freedom from valve failure and
ysfunction was disappointing (50% at 10 years). Recently
e examined the long-term fate of bioprosthetic pulmonary
alves and showed that approximately 80% would require
eoperation or manifest valve dysfunction by 10 years (11).
ertainly, this limited durability of bioprosthetic valves is a
eak facet in determining the optimal timing of PVR.
Our study showed significant reduction in QRS dura-
ion and excellent freedom from arrhythmias after PVR.
here have been conflicting results regarding the impact
f PVR on QRS duration and arrhythmia propensity, and
his might be due to the different characteristics of the
tudy populations. Studies reporting no change of QRS
uration enrolled patients with relatively longer baseline
RS duration or larger RV volumes compared with those
eporting improvement in QRS duration (9,14,26,33,36).
his implies that timely PVR before severe RV dilation
ccurs may have a beneficial effect on QRS duration, and
ur data support this speculation. As for the arrhythmia
ropensity after PVR, we found a very low rate of
rrhythmia occurrence. Only 1 patient developed new-
nset atrial flutter, and 2 patients showed recurrence of
trial fibrillation despite a concomitant maze procedure.
f note, no patient developed VT during follow-up.
arrild et al. (26) and Gengsakul et al. (36) found no
ignificant improvement in the frequency of arrhythmias
fter PVR. However, Therrien et al. (14) reported a
eduction in the incidence of atrial and ventricular
achyarrhythmias in conjunction with intraoperative
ryoablation. We think that it is important to incorporate
ntiarrhythmia surgery into PVR, if indicated, to reduce
he incidence of post-PVR arrhythmias.
utcome
Multivariable Analysis
Value OR (95% CI) p Value
.824
.294
.001
.001 1.06 (1.01–1.11) 0.021
.012 1.03 (0.92–1.14) 0.614
.013 1.01 (0.90–1.13) 0.898
.539
.064
.292
.470al O
sis
p
0
0
0
0
0
0
0
0
0
0ng correlation with RV ESVI (r  0.90; p  0.001).
s 1 and 3.
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September 11, 2012:1005–14 Optimal Timing of Pulmonary Valve ReplacementOptimal timing of PVR. Using MRI, we showed signif-
icant reduction (approximately 40%) of RV volumes and
improvement in biventricular function after PVR. Although
previous studies have consistently reported significant re-
duction of RV volumes, there have been conflicting results
regarding the improvement of RV function after PVR.
Studies reporting no improvement of RV function had
patients with already depressed RV function (RV EF
49%), whereas studies reporting improvement in RV
function had patients with preserved RV function
(7,8,16,23,25,26). This implies that PVR should be per-
formed before irreversible RV dysfunction occurs, and our
data support this notion. Of note, we also found a signifi-
cant increase in LV EDVI and improvement LV function,
suggesting reversal of adverse RV to LV interaction.
The main focus of our study was to better define the
optimal timing of PVR. If PVR can be performed with
negligible mortality and morbidity, and durable prosthetic
valves are available, PVR should be recommended as early as
possible for all patients with dilated RV. However, because
this is not the case, we should decide the “upper threshold”
to which point we can delay PVR and above which optimal
outcome cannot be expected after PVR. Therrien et al. (16)
rst reported this “upper threshold” (RV EDVI 170
l/m2 and RV ESVI 85 ml/m2). We found that optimal
outcome (normalized RV volumes and function) might not
be achieved when pre-operative RV EDVI was 163
l/m2 or RV ESVI was 80 ml/m2. Interestingly, these
cutoff values are very close to those reported by Oosterhof et
al. (9) (RV EDVI160 ml/m2 and RV ESVI82 ml/m2),
although their cutoff values were only for normalization of
RV volumes. Geva et al. (7) reported that RV ESVI 90
l/m2 was associated with optimal outcome. Frigiola et al.
8) suggested the most aggressive policy of performing PVR
hen RV EDVI is 150 ml/m2. What about the “lower
threshold” above which we should consider PVR? It defi-
nitely depends primarily upon the clinical status of an
individual patient. In asymptomatic patients, Dave et al.
(18) and Geva (20) recommended PVR when RV EDVI is
150 ml/m2.
Although many studies identified cutoff values of RV
DVI as an indication for PVR, Geva et al. (7) and
enkens et al. (24) stressed the importance of RV ESVI in
etermining the timing of PVR. Our MRI data showed a
trong correlation between post-operative RV ESVI and
V EF (r  0.76) (Fig. 3F) but only a modest correlation
etween post-operative RV EDVI and RV EF (r0.35).
herefore, achieving normal RV ESVI after PVR might be
ore important for improving post-PVR RV function. And
ccording to our regression analysis between pre-operative
V EDVI and ESVI (RV EDVI  1.21  RV ESVI 
61.2; r 0.90), our cutoff value of 163 ml/m2 for RV EDVI
corresponds to an RV ESVI of 84 ml/m2, which is above
our cutoff value. Higher pre-operative RV ESVI was iden-
tified as an independent risk factor for suboptimal outcome
in our study. Based upon our findings, we also suggest thatmore emphasis should be placed on RV ESVI in determin-
ing the timing of PVR.
Study limitations. Pre-operative electrocardiographic data
were available only in 79 patients (46%) owing to the data
loss during conversion of our medical record system. Car-
diopulmonary exercise testing data were not sufficient to
draw a meaningful conclusion. The variable time interval
between PVR and post-operative MRI study is another
limitation of our study.
Conclusions
Midterm outcomes of PVR in patients with chronic PR
were acceptable. To achieve an optimal outcome, PVR
should be considered before RV EDVI exceeds 163 ml/m2
or RV ESVI exceeds 80 ml/m2, with more attention to RV
SVI.
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